ECI Therapeutics
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
With an initial focus in ophthalmology, ECI is a biotech company focusing on innovative treatments for epithelial disorders using human platelet-rich plasma (PRP) derived growth factors. Our goal is to transform the treatment landscape for conditions like neurotrophic keratitis (NK) and dry eye disease (DED) with a safe allogeneic version of serum-like eye drops.
ECI's NK treatment, which we expect to have enter Phase II clinical trials in 2026, has gained orphan drug status from the FDA, which we expect will expedite product approval and ultimately enhance reimbursement.
Beyond NK, ECI expects our platform technology to be highly effective in treatment of other epithelial and endothelial injuries including dry eye disease, ophthalmic burns, ocular surface disorders, dermal (skin) burn, ulcers and diabetic ulcers.
Our pipeline and more information is available at www.ecitherapeutics.com
Address
CambridgeMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}